Thermo Fisher Scientific Inc. $TMO Shares Sold by BLI Banque de Luxembourg Investments

BLI Banque de Luxembourg Investments reduced its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 12.5% in the 4th quarter, HoldingsChannel.com reports. The fund owned 65,660 shares of the medical research company’s stock after selling 9,420 shares during the quarter. Thermo Fisher Scientific comprises approximately 1.1% of BLI Banque de Luxembourg Investments’ holdings, making the stock its 25th largest position. BLI Banque de Luxembourg Investments’ holdings in Thermo Fisher Scientific were worth $38,319,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of the company. Brighton Jones LLC grew its position in shares of Thermo Fisher Scientific by 28.9% during the fourth quarter. Brighton Jones LLC now owns 4,409 shares of the medical research company’s stock worth $2,293,000 after buying an additional 988 shares in the last quarter. Revolve Wealth Partners LLC grew its position in shares of Thermo Fisher Scientific by 4.2% during the fourth quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company’s stock worth $255,000 after buying an additional 20 shares in the last quarter. Darwin Wealth Management LLC acquired a new position in Thermo Fisher Scientific in the second quarter valued at approximately $170,000. Raymond James Financial Inc. boosted its holdings in Thermo Fisher Scientific by 7.4% in the second quarter. Raymond James Financial Inc. now owns 778,822 shares of the medical research company’s stock valued at $315,781,000 after purchasing an additional 53,542 shares in the last quarter. Finally, California State Teachers Retirement System boosted its holdings in Thermo Fisher Scientific by 0.4% in the second quarter. California State Teachers Retirement System now owns 602,031 shares of the medical research company’s stock valued at $244,099,000 after purchasing an additional 2,262 shares in the last quarter. 89.23% of the stock is owned by institutional investors and hedge funds.

Thermo Fisher Scientific Price Performance

Thermo Fisher Scientific stock opened at $469.41 on Tuesday. Thermo Fisher Scientific Inc. has a 12 month low of $385.46 and a 12 month high of $643.99. The company has a debt-to-equity ratio of 0.77, a current ratio of 1.53 and a quick ratio of 1.15. The business has a 50 day simple moving average of $479.56 and a 200-day simple moving average of $530.08. The stock has a market capitalization of $174.44 billion, a PE ratio of 25.81, a price-to-earnings-growth ratio of 2.09 and a beta of 0.88.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings results on Thursday, April 23rd. The medical research company reported $5.44 EPS for the quarter, topping the consensus estimate of $5.25 by $0.19. Thermo Fisher Scientific had a return on equity of 16.86% and a net margin of 15.15%.The business had revenue of $11.01 billion during the quarter, compared to analysts’ expectations of $10.86 billion. During the same quarter in the prior year, the business earned $5.15 earnings per share. The company’s quarterly revenue was up 6.2% compared to the same quarter last year. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. Equities analysts predict that Thermo Fisher Scientific Inc. will post 24.86 earnings per share for the current year.

Thermo Fisher Scientific Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, July 15th. Shareholders of record on Monday, June 15th will be given a $0.47 dividend. The ex-dividend date is Monday, June 15th. This represents a $1.88 annualized dividend and a yield of 0.4%. Thermo Fisher Scientific’s dividend payout ratio is presently 10.34%.

Insider Buying and Selling at Thermo Fisher Scientific

In other news, COO Gianluca Pettiti sold 400 shares of the company’s stock in a transaction on Monday, April 27th. The shares were sold at an average price of $462.66, for a total transaction of $185,064.00. Following the transaction, the chief operating officer directly owned 25,051 shares of the company’s stock, valued at $11,590,095.66. This represents a 1.57% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.33% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

TMO has been the subject of a number of research analyst reports. Wells Fargo & Company lowered their price target on Thermo Fisher Scientific from $675.00 to $615.00 and set an “overweight” rating for the company in a report on Friday, May 8th. Barclays lowered their price target on Thermo Fisher Scientific from $650.00 to $625.00 and set an “overweight” rating for the company in a report on Tuesday, April 14th. Morgan Stanley reaffirmed an “overweight” rating and issued a $620.00 price target on shares of Thermo Fisher Scientific in a report on Monday, April 27th. KeyCorp reaffirmed an “overweight” rating on shares of Thermo Fisher Scientific in a report on Tuesday, May 26th. Finally, HSBC downgraded Thermo Fisher Scientific from a “buy” rating to a “hold” rating and lowered their price target for the company from $670.00 to $540.00 in a report on Wednesday, June 3rd. Two analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and four have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $613.67.

About Thermo Fisher Scientific

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.